These data show an upregulation of AKT3 expression in AML samples carrying mutations in SRSF2, U2AF1, SRSF3, ASXL1 or BCOR, and consistently in samples of patients who developed a leukemia after a MDS or a MPN. Here, SRSF2 is linked to leukemia.